Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Profit After Tax (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Profit After Tax data on record, last reported at -$120.4 million in Q4 2025.

  • For Q4 2025, Profit After Tax fell 50.96% year-over-year to -$120.4 million; the TTM value through Dec 2025 reached -$342.6 million, down 26.91%, while the annual FY2025 figure was -$342.6 million, 26.91% down from the prior year.
  • Profit After Tax reached -$120.4 million in Q4 2025 per VRDN's latest filing, down from -$34.6 million in the prior quarter.
  • Across five years, Profit After Tax topped out at -$14.0 million in Q3 2021 and bottomed at -$120.4 million in Q4 2025.
  • Average Profit After Tax over 5 years is -$53.0 million, with a median of -$48.1 million recorded in 2023.
  • The widest YoY moves for Profit After Tax: up 68.1% in 2021, down 179.16% in 2021.
  • A 5-year view of Profit After Tax shows it stood at -$28.9 million in 2021, then tumbled by 58.17% to -$45.8 million in 2022, then tumbled by 46.03% to -$66.9 million in 2023, then fell by 19.24% to -$79.7 million in 2024, then plummeted by 50.96% to -$120.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Profit After Tax were -$120.4 million in Q4 2025, -$34.6 million in Q3 2025, and -$100.7 million in Q2 2025.